ArticleBlood cancer journal2026
Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium.
Aimaz Afrough et al.PubMed ↗Publisher ↗
No numbers read from the abstract.